Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.
BMJ Open
; 11(12): e050051, 2021 12 31.
Article
em En
| MEDLINE
| ID: mdl-34972763
ABSTRACT
OBJECTIVES:
SARS-CoV-2 enters cells using the ACE2 receptor. Medications that affect ACE2 expression or function such as angiotensin receptor blockers (ARBs) and ACE inhibitors (ACE-I) and metformin have the potential to counter the dysregulation of ACE2 by the virus and protect against viral injury. Here, we describe COVID-19 survival associated with ACE-I, ARB and metformin use.DESIGN:
This is a hospital-based observational study of patients with COVID-19 infection using logistic regression with correction for pre-existing conditions and propensity score weighted Cox proportional hazards models to estimate associations between medication use and mortality.SETTING:
Medical record data from the US Veterans Affairs (VA) were used to identify patients with a reverse transcription PCR diagnosis of COVID-19 infection, to classify patterns of ACE inhibitors (ACE-I), ARB, beta blockers, metformin, famotidine and remdesivir use, and, to capture mortality.PARTICIPANTS:
9532 hospitalised patients with COVID-19 infection followed for 60 days were analysed. OUTCOMEMEASURE:
Death from any cause within 60 days of COVID-19 diagnosis was examined.RESULTS:
Discontinuation of ACE-I was associated with increased risk of death (OR 1.4; 95% CI 1.2-1.7). Initiating (OR 0.3; 95% CI 0.2-0.5) or continuous (OR 0.6; 95% CI 0.5-0.7) ACE-I was associated with reduced risk of death. ARB and metformin associations were similar in direction and magnitude and also statistically significant. Results were unchanged when accounting for pre-existing morbidity and propensity score adjustment.CONCLUSIONS:
Recent randomised clinical trials support the safety of continuing ACE-I and ARB treatment in patients with COVID-19 where indicated. Our study extends these findings to suggest a possible COVID-19 survival benefit for continuing or initiating ACE-I, ARB and metformin medications. Randomised trials are appropriate to confirm or refute the therapeutic potential for ACE-I, ARBs and metformin.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antagonistas de Receptores de Angiotensina
/
COVID-19
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article